Metropolis Healthcare reported strong financial results for Q2 2024-2025, showcasing improvements in interest management, debt reduction, and cash flow generation. The company's Operating Profit to Interest ratio reached 18.76 times, while net sales hit Rs 349.79 crore, leading to a recommendation from MarketsMojo to hold the stock. Despite positive trends in profitability, challenges remain in short-term liquidity, with cash reserves at Rs 54.36 crore.
